Immunome Inc.
corporate_fare Company Profile
Immunome Inc. (NASDAQ:IMNM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for IMNM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for IMNM spans 8-K, 10-Q, 144, 4.
Recent high-impact activity:
- Q3 Loss Widens to $85.8M as Cash Runway Extends Into 2028
- Varegacestat Phase 3 PRO Data Show Symptom, Function Gains in Desmoid Tumors
- Immunome Buys Out BMS Royalties on Varegacestat for $20M Cash Plus 4.4M Shares
- FDA Clears IND for Immunome's First-in-Class ADC IM-1340
- Immunome Reports Widening Q2 Loss, Advances Pipeline with Varegacestat NDA Acceptance and New Phase 1 Trials
Financial Snapshot
Short Interest & Short Volume
12.77 days to coverFINRA reported short interest of 16,173,694 shares in IMNM as of the October 30, 2026 settlement, a 6.4% decrease from the prior period — about 12.8 days to cover at its recent average daily volume. On November 20, 2026, 43.4% of IMNM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IMNM, detected from its recent SEC filings · based on capital-structure filings through 2026-11-09.
New $134.1M ATM Capacity Established · Prior ATM Already Drew $65.9M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →